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NOVELTY STATEMENT  
 This study evaluates the performance of a novel, pre-production version of a home oral 
glucose tolerance testing device 
 The device was easy to use, with an excellent device success rate and showed good agreement 
with 2 separate laboratory analysers in both normal glucose tolerance and glucose intolerance 
 Our findings demonstrate that the device offers an alternative to clinic-based OGTT testing, 
with the potential for the test to be performed conveniently at home or in a community 
setting 
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ABSTRACT 
Aims: To evaluate the performance of the current, pre-production version of a novel Home OGTT 
device when administered by trained research nurses, compared to a reference laboratory glucose 
analyser and a second laboratory analyser, incorporating a sample processing delay to simulate 
normal practice.  
Methods: One hundred women (19 to 48 years), with and without known glucose intolerance were 
recruited. Following an overnight fast, participants attended for a 75g OGTT. A fasting capillary sample 
was applied to the Home OGTT device with a corresponding venous sample collected and measured 
immediately on the reference YSI 2300 stat plus analyser, and following a 1 hour delay on the Randox 
Daytona plus analyser. The sampling process was repeated 2 hours after the oral glucose load.  
Results: 97% of tested devices gave complete data for analysis. Good agreement was observed 
between the reference glucose analyser and the Home OGTT device, with the Home OGTT device 
displaying a small negative bias (-0.18mmol/l [-1.75 to 1.39] / -1.0% [-26.4 to 24.5]). When classified 
as normal glucose tolerant or glucose intolerant, the Home OGTT device showed 100% and 90% 
sensitivity and 99% and 99% specificity using FPG and 2 hour glucose respectively. Similar sensitivity 
(100% and 100%) and specificity (96% and 99%) for FPG and 2 hour glucose were observed using the 
secondary analyser.  
Conclusions: The novel Home OGTT device was reliable and easy to use and showed excellent 
agreement with 2 separate laboratory analysers. The Home OGTT offers potential as an effective 
alternative for clinic-based OGTT testing.  
 
  
INTRODUCTION 
Traditionally, diagnosis of the various classifications of glucose intolerance has been achieved by 
performing an Oral Glucose Tolerance Test (OGTT) [1, 2]. More recently, measurement of glycated 
haemoglobin (HbA1c) has been employed as the diagnostic test [3-6], however there remain situations 
where HbA1c is not suitable for diagnosis, including its use in people with abnormal or variant 
haemoglobins, anaemia and conditions altering the lifespan of the red blood cell [7].  Many studies 
show HbA1c has poor sensitivity and specificity compared to OGTT for the detection of IGT, however 
performing an OGTT can be expensive, inconvenient and difficult to provide, and therefore 
measurement of HbA1c is often the only viable option. 
In clinical settings where OGTT is the only recommended test, for example for gestational diabetes 
(GDM) in pregnancy and for cystic fibrosis related diabetes [8, 9], poor availability and accessibility of 
OGTT often leads to low compliance.  A novel test kit has been developed that offers the potential for 
untrained individuals to perform an OGTT conveniently at home or in a community setting.  The 
SmartSensor Telemed (SSt) Home OGTT device is an electronic device that has a wireless detachable 
data record that can be either returned for reading or scanned by smartphone with results uploaded 
to a Web based database for data processing and generation of test results. The Home OGTT device 
does not provide a result directly to the user. An evaluation of an early prototype version of this device 
has been described previously in 2013 [8], in people both with and without type 2 diabetes. While the 
device was well accepted by participants and showed good reproducibility across study visits, a 
positive bias was observed which increased at high glucose levels and there were a significant number 
of device failures. An editorial in the same edition of the journal suggested that if calibration and 
device failure rates were addressed, self-administered OGTT could impact future screening and 
diagnosis of diabetes [9].  
The aim of this study was to evaluate the current version of the Home OGTT device, that has 
incorporated hardware and calibration improvements informed by the findings of the previous 2013 
study [8]. The devices were tested in a study cohort similar to those at risk of GDM (except participants 
did not need necessarily to be pregnant), a population who could potentially benefit from the 
convenience offered by the device. The performance during an OGTT was compared to that of two 
different laboratory analysers; one measured immediately as the ‘reference’ result and a second 
processed and measured after a period of an hour, to more closely reflect the situation in a routine 
clinic.  
 
PARTICIPANTS AND METHODS 
This study was performed between April 2017 and June 2018 at the Joint Clinical Research Facility, 
ILS2, Swansea University, Swansea, UK, in compliance with Good Clinical Practice. Ethical approval was 
obtained from Wales REC 6 (17/WA/0079) prior to commencement of the study.  All test procedures 
were carried out by research staff.  
Participants 
One hundred women aged 19 to 48 years inclusive, with and without known glucose intolerance and 
with a BMI ≥25 kg/m2 were recruited into the study. The sample size of 100 participants was 
established following an interim statistical review of the data after 60 completed participants. 
 
Home OGTT device 
The Home OGTT devices were provided by SmartSensor telemed (Didcot, UK). The device consisted of 
2 glucose dehydrogenase test strips (0 and 2 hour) with user activated buttons. The test procedure 
was driven by an integral clock and timer, with audible and visual prompts.  
Each single-use, disposable device was stored in sealed packaging, and opened immediately prior to 
use. Full instructions to guide the user through the complete OGTT procedure were included. An 
example of the device with user instructions is shown in Figure 1. The process is similar to that 
described previously by Bethel et al [8]. Briefly, the device was activated by removing a protective 
cover over the 0 hour test strip and a capillary blood sample obtained using a lancet administered to 
the strip. After consuming the glucose drink, the ‘set’ button was pressed to begin the timer. After 2 
hours, an audible alarm alerted the user to press ‘stop’ and repeat the sampling process with the 2 
hour test strip. A further audible alarm confirmed the test was complete. Finally, the detachable data 
recorder was removed, scanned and the result automatically transferred to a secure Web based 
database. 
 
Study procedure 
All study procedures were performed by research nurses, fully trained in the use of the Home OGTT 
device. Following an overnight fast, all participants attended for a 75 gram OGTT. At time 0, a 
fingerprick capillary blood sample was applied to the 0 minute glucose sensor and the Home OGTT 
device timer initiated. From the same capillary sample, haematocrit was also measured (Hemo Control 
Haemoglobin Analyser, EKF Diagnostics, Penarth, UK). At the same time, a corresponding venous 
blood sample was taken into a sodium fluoride /potassium oxalate vacutainer (Becton Dickinson, 
Berks, UK) for determination of plasma glucose on 2 laboratory analysers utilising glucose oxidase. 
Following the blood collection, a drink containing the 75g glucose (Polycal, Nutricia, Trowbridge, UK) 
was consumed. After 2 hours, the glucose sampling was repeated. Following this the detachable data 
recorder was removed, scanned and the result automatically transferred to a database. 
 
Laboratory measurements 
Venous blood in sodium fluoride / potassium oxalate, was immediately aliquoted into 2 separate 
tubes. The first tube was centrifuged immediately for 5 minutes and the plasma decanted and 
measured (YSI 2300 stat plus, Yellow Springs Instruments, Hants, UK). This YSI glucose value was 
considered the ‘reference’ value. The second tube was centrifuged for 5 minutes after a period of an 
hour, to simulate the delay in processing and measurement that may be expected in routine practice. 
This ‘routine’ sample was subsequently measured using a Randox Daytona Plus analyser (Randox 
Laboratories Ltd., County Antrim, UK). Daily internal quality control samples were run prior to any 
study samples (Assayed Chemistry Control Plus, levels 2 and 3, Randox Laboratories, County Antrim, 
UK). 
Due to the difficulty in obtaining venous blood from a small number of participants, the reference YSI 
sample was prioritised and consequently fewer ‘routine’ samples were available for analysis using the 
Randox Daytona Plus analyser.  
 
Data analysis 
Method comparison was assessed using Bland Altman plots (absolute and relative bias) of the Home 
OGTT device versus the reference YSI values.  
To view the results in a more clinical context, participants were categorised as normal glucose tolerant 
or glucose intolerant according to the WHO (2006) criteria. Agreement of the diagnoses generated 
using the Home OGTT device and the routine Daytona plus lab analyser with the reference YSI analyser 
were assessed using Receiver Operating Characteristics (ROC) curves (sensitivity and specificity) and 
positive and negative predictive values (PPV and NPV) [10].  
 
RESULTS 
Demographic characteristics 
Mean (SD) age, BMI and haematocrit of the participants was 35.8 (7.84) years, 33.9 (5.97) kg/m2 and 
39.1 (4.07) % respectively. The measured glucose concentrations ranged from 3.13 to 23.2 (5.37 [4.71, 
6.54]) mmol/l (median [25th,75th percentiles) on the reference YSI analyser and from 3.25 to 20.47 
(5.22 [4.64, 6.46]) mmol/l (median [25th, 75th percentiles]) on the Home OGTT devices. 
Comparison of SST OGGT device with YSI analyser 
Of the 100 Home OGTT devices used, 3 devices failed to generate one or both results (1 generated a 
fasting result only, one generated a 2 hour result only and 1 failed to generate either result), meaning 
a total of 98 fasting and 98 2 hour results were included for comparison.  
Good agreement was observed between the reference YSI and Home OGTT device glucose, with a 
small negative bias (-0.18 mmol/l [-1.75 to 1.39mmol/l] and -1.0% [-26.4 to 24.5%]; absolute and 
relative mean [95% limits of agreement] bias, respectively) observed for the Home OGTT device 
compared to the YSI glucose values (Figure 2 A and B).  
Diagnosis / Interpretation 
Participants were classified as glucose intolerant by either fasting plasma glucose (FPG) ≥6.1 mmol/l 
or 2 hour plasma glucose (PG) ≥7.8 mmol/l or a combination of both (FPG≥6.1 and/or 2 hour PG ≥7.8 
mmol/l) by all analytical methods (Home OGTT device, YSI and Randox Daytona Plus), with the 
diagnosis using the YSI taken as the reference diagnosis. 
The sensitivity and specificity of the Home OGTT device and Randox Daytona Plus analyser are shown 
in Table 1 and ROC curves shown in Figure 3. The Home OGTT device showed 100% and 90% sensitivity 
using the FPG and 2 hour glucose respectively, with corresponding specificity of 99% for both. Similar 
sensitivity (FPG and 2 hour PG 100%) and specificity (96% and 99%; FPG and 2 hour PG respectively) 
were observed with the Randox Daytona Plus. 
Positive (PPV) and Negative (NPV) values for device and routine are shown in Table 2. Home OGTT 
device PPV and NPV all exceeded 90% versus the YSI diagnosis by FPG only, 2 hour PG only and 
combined FPG and 2 hour PG. For the Randox Daytona Plus, the respective PPVs were slightly lower 
but displayed NPVs of 100% for all diagnoses. 
DISCUSSION 
Although measurement of HbA1c is commonly used as a diagnostic test for diabetes, there remain 
situations where HbA1c is not suitable and an OGTT needs to be performed. In clinical settings where 
OGTT is the recommended test, for example for gestational diabetes in pregnancy and for cystic 
fibrosis related diabetes, poor availability and accessibility of OGTT often leads to low compliance. A 
novel test kit has been developed with the intention that untrained individuals can perform the OGTT 
conveniently at home providing a convenient alternative to a conventional clinic-based test. In this 
study, the performance of the novel Home OGTT device was evaluated in a cohort of overweight 
women of childbearing age and compared to the concentrations and diagnoses obtained using two 
separate laboratory analysers.  
Out of a total of 100 tested devices, 97 generated both fasting and 2 hour results, illustrating the 
reliability and ease of use of the device in its present pre-production form. Across a wide glucose 
concentration range, the device performed well with good agreement with the reference glucose 
analyser, with a small negative bias observed for the Home OGTT device. When classed as glucose 
intolerant by the reference glucose analyser, the device displayed very high sensitivity and specificity 
for both fasting and 2 hour results. In addition, compared to the reference analyser, the device positive 
and negative predictive values were very high.  
A previous study [8] using an earlier prototype version of the device demonstrated ease of use, both 
by nurses and untrained volunteers, however a significant device failure rate (22%) and positive bias 
(0.4 mmol/l and 3.1  mmol/l for fasting and 2 hour glucose respectively) which increased at higher 
glucose concentrations was observed. In our study the  high device success rate and small overall bias, 
illustrates that the hardware and calibration changes implemented in these pre-production devices 
have resulted in a significant improvement in performance. 
In routine practice during an OGTT, there is generally a delay between sample collection and 
processing and analysis in the laboratory. To simulate this delay, an aliquot of each collected venous 
sample was left unprocessed for a period of an hour, before centrifuging and analysing on a second 
glucose analyser (Randox Daytona Plus). Compared to the reference YSI diagnosis, the sensitivity and 
specificity of the routinely handled samples was equivalent to that of the Home OGTT device, with 
similar agreement observed.  
The limitations of this study are that the evaluation was performed in a specific population, with the 
OGTT procedures performed by research nurses trained in the use of the device. This was to establish 
the improvements in performance characteristics of the current version of the device in a controlled 
setting, prior to testing under ‘real-life’ conditions. Further studies will be required to determine 
whether the performance we have observed is comparable across a more diverse participant group, 
reflecting that of the overall population and also when the procedures are performed by the 
participants themselves, without input from research staff. 
The excellent agreement between the Home OGTT device and laboratory analysers makes it an 
effective alternative for clinic-based OGTTs, and in particular in parts of the world where the use of 
HbA1c is limited by common clinical conditions, e.g., haemoglobinopathies, anaemia, the cost or 
availability of laboratory facilities, or the lack of trained staff to perform the test. As the device does 
not give glucose values or diagnostic information directly to the user, interpretation of the results will 
remain with the health care provider who can then offer the most appropriate advice or treatment 
options. The Home OGTT device is also easy to use giving the potential for a significant improvement 
in compliance with uptake. The SSt Home OGTT device offers a convenient, cost-effective route to 
detecting prediabetes and diabetes or as a research tool, being far more sensitive and specific than 
HbA1c and fasting glucose.  
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Glucose 
intolerant by: 
 Device  Routine lab analyser 
N Sensitivity Specificity N Sensitivity Specificity 
FPG 
(≥6.1mmol/l) 
98 1.000 0.988 90 1.000 0.961 
2 hour  PG 
(≥7.8mmol/l) 
96 0.900 0.987 83 
 
1.000 0.986 
 
Table 1  ROC analysis with sensitivity / specificity for both device and routine laboratory 
analyser compared to reference YSI diagnosis 
 
  
Glucose intolerant 
by: 
Device Routine lab analyser 
PPV NPV PPV NPV 
FPG (≥6.1mmol/l) 
 
0.941 1.000 0.824 1.000 
2 hour  PG 
(≥7.8mmol/l) 
0.947 0.974 0.933 1.000 
FPG ≥6.1 and/or 2 
hour PG 
≥7.8mmol/l 
0.909 0.973 0.850 1.000 
  
Table 2 Positive (PPV) and negative (NPV) predictive values for both device and routine 
laboratory analyser compared to reference YSI diagnosis 
  
FIGURE LEGENDS 
Figure 1 Example of device including user instructions 
Figure 2 Absolute (a) and relative (b) bias. Solid blue line = bias, broken lines = 95% limits of 
agreement.  
Figure 3 ROC curves for Home OGTT device using (a) FPG (b) and 2 hour glucose and Randox 
Daytona Plus using (c) FPG and (d) 2 hour glucose respectively against reference YSI 
2300 classification  
 
  
 
 
